Clinical Trial Update: TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating TQB2450 plus progestin for fertility-sparing treatment in mismatch repair-deficient endometrial cancer is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Progestin (Progestin)
• TQB2450

Snippet

Sponsor: Fudan University | Conditions: Endometrial Cancer | Phase 2 | Status: RECRUITING